CDX2 + CK7
Price range: $970.00 through $3,406.00
Description
Product Description
Studies show CDX2 is a sensitive marker for colonic carcinoma metastatic to the ovary and is more specific than CK20 as it is not expressed by serous and endometrioid carcinomas. CDX2 is also expressed in mucinous ovarian carcinomas. CDX2 is reported to be advantageous over CK20 for distinguishing primary ovarian tumors from metastases of upper gastrointestinal tract origin. Cytokeratin 7 shows expression in primary ovarian tumors and metastases of upper gastrointestinal tract origin. A CDX2 and CK7 panel may help in distinguishing colonic carcinomas metastatic to the ovaries from primary ovarian carcinomas.
Specifications
Specifications
| Weight | N/A |
|---|---|
| Dimensions | N/A |
| Intended Use | |
| Species Reactivity | |
| Source | |
| Clone | |
| Isotype | |
| Antigen | |
| Localization | |
| Positive Control |
Datasheets & SDS
| Download Data Sheet |
| Download RUO Data Sheet for International |
| Download SDS Sheet |
Browse more documents for this product (IFUs, datasheets, translations, SDS, and more).
Regulatory Notice: Biocare’s IVD-labeled products comply with US-FDA and European IVDD regulation. Other regions may have additional requirements for such labeling, please contact your local distributor.
References
1. Kim MJ. J Korean Med Sci. 2005 Aug; 20(4):643-8.
2. Vang R, et al. Mod Pathol. 2006 Nov; 19(11):1421-8.
3. Werling RW, et al. Am J Surg Pathol. 2003 Mar; 27(3):303-10.
4. Raspollini MR, et al. Appl Immunohistochem Mol Morphol. 2004 Jun; 12(2):127-31.
5. Groisman GM, Meir A, Sabo E. Int J Gynecol Pathol. 2004 Jan; 23(1):52-7.
